| http://www.w3.org/ns/prov#value | - These agents can be administered to a patient suffering from a disorder such as muscle wasting disease, neuromuscular disorder, muscle atrophy, obesity or other adipocyte cell disorders, and aging, for example.The invention also provides a method for a method for identifying a compound that affects GDF-8 activity or gene expression including incubating the compound with GDF-8 polypeptide, or with
|
